Group 1: Market Overview - The domestic market indices showed positive performance with the Shanghai Composite Index closing at 3510, up by 0.48% on the day and 1.40% for the week [1] - The overseas markets also experienced mixed results, with the Dow Jones Index closing at 44458, up by 0.49% on the day and 2.30% for the week [2] Group 2: Key Recommendations - The report from Ping An Securities highlights the ongoing "anti-involution" market phase, indicating that the current market is still in the expectation catalysis stage, with significant gains observed in sectors like photovoltaic, steel, and cement, averaging 3%-8% during the period from July 2-7 [3][10] - The report suggests focusing on industries with lower capacity utilization and higher profit pressure, particularly in the photovoltaic sector, construction materials, and certain light industry sectors [10] Group 3: Fund Performance - As of the end of June 2025, the total number of fund advisory combinations on the Tian Tian Fund APP reached 446, an increase of 5 from the previous month, indicating a growing interest in fund management [4][11] - The performance of various fund types showed that military, smart manufacturing, healthcare, consumer, and dividend strategies outperformed their benchmarks, while new energy, technology, and gold strategies lagged [12] Group 4: Industry Insights - The report emphasizes the importance of government policies in addressing "involution" competition, with recent meetings highlighting the need for industry self-regulation and quality improvement [7][8] - Historical comparisons indicate that the current "anti-involution" measures differ from previous supply-side reforms, focusing more on market-driven approaches rather than administrative measures [8][9] Group 5: New Stock Overview - Upcoming IPOs include Shanda Electric Power with an issue price of 14.66 and a subscription limit of 1 million shares, and Jiyuan Group with an issue price of 10.88 and a subscription limit of 1.2 million shares [15]

Group 1: "Anti-Involution" Framework - The government has shifted its focus from merely preventing "involution" to a comprehensive rectification of "involution-style" competition, emphasizing the need for industry self-discipline and the elimination of local protectionism [5][6][8] - Recent high-level meetings have highlighted the importance of addressing "involution-style" competition, with specific measures aimed at promoting a unified national market and improving regulatory frameworks [5][6][8] Group 2: Supply-Side Reform Review - The previous supply-side reform focused on reducing excess capacity in traditional industries through administrative measures, while the current "anti-involution" approach aims to mitigate low-price competition in emerging industries using market-oriented methods [2][17] - The supply-side reform from 2015 to 2017 resulted in significant capacity reductions, with over 170 million tons of steel and 1 billion tons of coal capacity eliminated, leading to improved profitability in related sectors [18][19] Group 3: Market Outlook - The current "anti-involution" market is still in the expectation catalysis phase, with industries like photovoltaic and steel showing positive performance, while others like lithium batteries and e-commerce are lagging [2][3] - The report suggests that industries with lower capacity utilization and higher profit pressures are more likely to self-correct, indicating a potential for improvement in sectors such as photovoltaic equipment and construction materials [2][3] Group 4: Industry-Specific Measures - The government is promoting industry self-discipline and innovation, with initiatives encouraging companies to enhance product quality and phase out outdated capacities [7][14] - Specific industries, including photovoltaic, steel, and cement, are being targeted for regulatory measures to curb low-price competition and promote sustainable development [7][14][16]

Group 1 - The report indicates an increase in active equity positions, with a preference for dividend strategies and cyclical theme funds [4][10][27] - As of the end of June 2025, there are 446 fund advisory combinations on the Tian Tian Fund APP, an increase of 5 from the previous month, with a notable dominance of equity-debt central combinations [10][11] - The performance of the equity-debt central combinations shows that the aggressive type outperformed similar FOF products over the past year, while balanced and conservative types underperformed [16][19] Group 2 - The report highlights that the active equity funds favored by advisory combinations include cyclical themes, dividend strategies, growth styles, value themes, and technology themes [41][46] - The QDII funds that received significant allocations include the Huaxia Hang Seng Technology ETF and the Southern Nasdaq 100 A [47][52] - The report notes that the most favored passive equity funds include those focused on low volatility dividend strategies and Hong Kong banking sectors [53][54] Group 3 - The report tracks the changes in fund positions, indicating that conservative combinations reduced mixed funds while increasing index funds, and aggressive combinations reduced passive equity funds while increasing active equity funds [34][40] - The report also details the top ten active equity funds favored by advisory combinations, with a focus on value style and cyclical themes [43][46] - The report provides insights into the performance of thematic and regional advisory combinations, noting that the medical and renewable energy sectors outperformed their benchmarks [25][27][31]

其 他 报 告 2025年07月10日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3493 | -0.13 | 1.40 | | 深证成份指数 | 10582 | -0.06 | 1.25 | | 沪深300指数 | 3991 | -0.18 | 1.54 | | 创业板指数 | 2185 | 0.16 | 1.50 | | 上证国债指数 | 226 | 0.00 | 0.16 | | 上证基金指数 | 6945 | -0.04 | 0.16 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 23892 | -1.06 | -1.52 | | 中国香港国企指数 | 8597 | -1.28 | -1.75 | | 中国台湾加权指数 | 22527 | 0.74 | -0.14 | | 道琼斯指数 | 44241 | ...

证券研究报告 月酝知风之银行业 ——股息仍具吸引力，关注长期资金入市 银行行业 强于大市（维持） 证券分析师 袁喆奇 投资咨询资格编号：S1060520080003 许淼 投资咨询资格编号：S1060525020001 研究助理 李灵琇 一般从业资格编号：S1060124070021 2025年7月9日 请务必阅读正文后免责条款 核心摘要 2 行业核心观点：资金结构深刻变化，顺势而为重配置轻交易。资金流向的变化是推动板块估值修复中不可忽视的力量，一方面被动指数的持续扩容带来了稳定的资金流入，板块 高权重的特征仍将持续推动资金的流入，一方面银行板块低波高红利的特征更易获得险资等中长期资金的青睐，目前板块平均股息率达到3.86%，结合监管一系列引导中长期资金 入市的措施，预计板块的股息配置价值吸引力仍将持续。个股维度，我们结合股息和潜在增量中长期资金流入空间看好A股股份行板块以及部分优质区域行（成都、北京、江苏、 上海、苏州、长沙），同时关注更具股息优势的港股大行配置机会。 行业热点跟踪：中长期资金趋势性流入，高股息价值投资持续。险资持续增配银行板块。24年以来险资增配速度略有提升，新会计准则运用之后保险资金为了 ...

Group 1: Oil and Petrochemical Industry - The core viewpoint indicates that strong performance in US crude oil exports and production, along with unexpected commercial crude oil inventory reductions, is expected to support gasoline and aviation fuel demand during the summer travel peak [2][8] - The report anticipates Brent crude oil prices to have strong support at $60 per barrel in Q3 2025, with potential upward price adjustments of $5 to $15 per barrel if geopolitical tensions in the Middle East escalate [2][8] - The report highlights that domestic oil companies are diversifying their oil supply sources and reducing sensitivity to oil price fluctuations through integrated upstream and downstream operations [9] Group 2: Banking Industry - The report notes a significant increase in the proportion of bill business among listed banks, with a rise of 0.98 percentage points to 5.7% by the end of 2024, indicating a shift in credit allocation towards more stable and lower-risk sectors [10][11] - The overall asset quality of the banking sector remains stable, with a slight decrease in the non-performing loan ratio to 1.22% and a decrease in the provision coverage ratio to 238% [11] - The report suggests that the banking sector's average dividend yield of 3.86% continues to attract long-term funds, with a positive outlook for A-share listed banks and select regional banks [12] Group 3: Healthcare and Pharmaceutical Industry - The report emphasizes that Chinese innovative pharmaceutical companies are reshaping the global pharmaceutical landscape by achieving better innovation outcomes at lower costs, with over $1 billion in revenue from domestic innovative drugs [4][14] - The report identifies three driving factors for the long-term growth of the innovative drug industry: sustained enthusiasm for business development (BD), breakthroughs in commercialization, and ongoing supportive policies [4][14] - The report highlights a significant increase in authorized transactions in the biopharmaceutical sector, with over 100 transactions in 2024, totaling approximately $52.3 billion, marking a 25% increase [14] Group 4: Technology and Computing Industry - The report indicates that the computing industry is expected to see a dual enhancement in performance and valuation due to accelerated demand recovery, particularly in the AI sector [17] - The report highlights Oracle's collaboration with OpenAI to develop multiple data centers across the US, reflecting the ongoing competition in the global AI computing market [17] - The report recommends focusing on companies with strong positions in the AI and cloud computing sectors, as well as those involved in the domestic electronic device manufacturing [22]

Core Insights - The Chinese innovative pharmaceutical industry is reshaping the global landscape by achieving similar or better innovation outcomes at lower costs and higher efficiency, leading to increased interest from multinational corporations (MNCs) in acquiring Chinese innovative assets [2][32] - The trend of business development (BD) in innovative drugs continues, with over 100 external licensing transactions in 2024, totaling approximately $52.3 billion, marking a 25% increase and a historical high [2][32] - Commercialization breakthroughs are evident, with a rising proportion of innovative drug companies in A-shares and Hong Kong stocks showing improved profitability in 2024 compared to 2023 [2][32] - Supportive policies for innovative drugs are being reinforced, with significant measures included in government work reports and specific plans to support the development of the innovative drug industry [2][32] Part 1: Market Review - As of June 15, 2025, the pharmaceutical sector has outperformed the broader market, with a 9.32% increase compared to a 1.80% decline in the CSI 300 index, resulting in an outperformance of 11.12 percentage points [6][13] - The pharmaceutical index has shown strong performance, particularly in the innovative drug sub-sector, which has been buoyed by favorable policies and improved profitability [8][16] Part 2: Innovative Drugs - The BD trend in innovative drugs is robust, with a total BD transaction amount reaching $50.1 billion by June 12, 2025, reflecting a 135% increase [2][32] - The commercialization of innovative drugs is gaining momentum, with a significant increase in the number of companies achieving profitability or reducing losses in 2024 compared to 2023 [2][32] - Supportive policies for innovative drugs have been increasingly emphasized, with the 2024 government work report highlighting the importance of the innovative drug sector [2][32] Part 3: CXO and Upstream - The industry environment is stable, with steady investment in innovation and a focus on new business areas such as peptides and antibody-drug conjugates (ADCs) [2][32] - Investment strategies suggest focusing on companies with strong capabilities and increasing market share in the domestic pharmaceutical innovation sector [2][32] Part 4: Medical Devices - The medical device sector is experiencing a recovery driven by numerous equipment upgrade projects entering the bidding phase, with expectations for continued growth in 2025 [2][32] - The ongoing procurement processes and inventory digestion among equipment companies are anticipated to lead to improved financial performance [2][32] Investment Recommendations - Focus on leading innovative drug companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group [2][32] - Consider companies with significant single product potential and price revaluation opportunities, such as Yipinhong and Sanofi [2][32] - Pay attention to companies with leading positions in advanced technology platforms, such as Dongcheng Pharmaceutical and Yuanda Medicine [2][32]

Investment Rating - The industry investment rating is "Outperform the Market" which indicates an expected performance that exceeds the market by more than 5% over the next six months [22]. Core Insights - Oracle is collaborating with OpenAI on computing power, developing multiple data centers across the U.S. This partnership is expected to sustain strong demand in the global computing power industry [3][4]. - The competition in large models remains intense, with companies like Baidu and Google launching new video generation models, further driving the demand for computing power [6]. - Beijing has released a three-year action plan for "AI + Healthcare," aiming to accelerate the integration of AI in the pharmaceutical industry, which is expected to enhance the digital transformation of the sector [8][10]. Summary by Sections Industry News and Commentary - Oracle's partnership with OpenAI involves the development of data centers in various U.S. states, with OpenAI renting approximately 4.5 gigawatts of power capacity [5]. - The global competition in AI models is intensifying, as evidenced by Baidu's and Google's recent model launches, which will maintain robust demand for computing power [6]. Key Company Announcements - Wanhua Technology announced its second employee stock ownership plan for 2025, aiming to raise up to 27.89 million yuan [12]. - China Software is set to issue 90,130,689 shares at a price of 22.19 yuan per share, raising nearly 2 billion yuan [12]. - Haima Data announced a stock option incentive plan for 2025, with a total of 17.66 million options to be granted [12]. Weekly Market Review - The computer industry index fell by 1.28% last week, underperforming the CSI 300 index, which rose by 1.54% [13]. - The overall P/E ratio for the computer industry is 51.7 times, with 106 out of 359 A-share stocks rising in price [15]. Investment Recommendations - The report suggests a strong outlook for the computer industry, recommending stocks in various sectors including: - Innovation and Creation sector: Longxin Zhongke, Kingsoft Office, and others [18]. - Huawei supply chain: Daotong Technology and Digital China [18]. - AI sector: Strong recommendations for Zhongke Chuangda and Shengshi Technology [18]. - Financial IT sector: Strong recommendation for Hengsheng Electronics [18]. - Low-altitude economy sector: Recommendations for companies like Wanfeng Aowei and Les Information [18].

Investment Rating - The report maintains a "Recommended" rating for the company [1][10]. Core Views - The company is expected to achieve a net profit attributable to shareholders of between 11.958 billion yuan and 12.158 billion yuan for the first half of 2025, representing a year-on-year growth of 36.84% to 39.12% [4][9]. - The second quarter net profit is projected to be between 6.727 billion yuan and 6.927 billion yuan, with a year-on-year increase of 47.72% to 52.11% [4][9]. - The significant growth in performance is attributed to the surge in AI-related business, with AI server revenue increasing by over 60% year-on-year in the second quarter [9][10]. - The company maintains a leading position in the market due to its strong relationships with major clients and its ability to develop products collaboratively [10]. Financial Performance Summary - Revenue for 2025 is projected to be 717.968 billion yuan, with a year-on-year growth of 17.9% [7][12]. - Net profit for 2025 is estimated at 29.210 billion yuan, reflecting a year-on-year increase of 25.8% [7][12]. - The gross margin is expected to be 6.7% in 2025, while the net margin is projected at 4.1% [7][12]. - Earnings per share (EPS) for 2025 is forecasted to be 1.47 yuan [7][12]. Business Segment Performance - The cloud computing business is experiencing rapid growth, with overall revenue increasing by over 50% year-on-year in the second quarter [9][10]. - The AI server segment's revenue is expected to grow significantly, driven by the demand for hyper-scale AI cabinet products [9][10]. - The company is also focusing on smart manufacturing and AI integration, which is expected to drive steady growth in its telecommunications and mobile network equipment business [9][10]. Market Position and Outlook - The company is positioned as a leader in high-end intelligent manufacturing of electronic devices, benefiting from advanced technology and a global customer base [10]. - The rapid development of the AI industry is expected to continue driving demand for computing power, high-speed network communication equipment, and servers, which will benefit the company's core businesses [10].

其 他 报 告 2025年07月08日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3473 | 0.02 | 1.40 | | 深证成份指数 | 10436 | -0.70 | 1.25 | | 沪深300指数 | 3965 | -0.43 | 1.54 | | 创业板指数 | 2130 | -1.21 | 1.50 | | 上证国债指数 | 226 | 0.06 | 0.16 | | 上证基金指数 | 6939 | -0.05 | 0.16 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 23888 | -0.12 | -1.52 | | 中国香港国企指数 | 8609 | -0.01 | -1.75 | | 中国台湾加权指数 | 22429 | -0.53 | -0.14 | | 道琼斯指数 | 44829 | ...